AU2000239309A1 - Insulin and igf-1 receptor agonists and antagonists - Google Patents

Insulin and igf-1 receptor agonists and antagonists

Info

Publication number
AU2000239309A1
AU2000239309A1 AU2000239309A AU3930900A AU2000239309A1 AU 2000239309 A1 AU2000239309 A1 AU 2000239309A1 AU 2000239309 A AU2000239309 A AU 2000239309A AU 3930900 A AU3930900 A AU 3930900A AU 2000239309 A1 AU2000239309 A1 AU 2000239309A1
Authority
AU
Australia
Prior art keywords
insulin
antagonists
peptides
igf
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000239309A
Other languages
English (en)
Inventor
James Beasley
Arthur J Blume
Jakob Brandt
Renee Brissette
Weiqing Cheng
Per Hertz Hansen
Ku-Chuan Hsiao
Wlodek S. Mandecki
Soren Ostergaard
Renuka Pillutla
Mark Ravera
Lauge Schaffer
Jane Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
DGI BioTechnologies LLC
Original Assignee
Novo Nordisk AS
DGI BioTechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, DGI BioTechnologies LLC filed Critical Novo Nordisk AS
Publication of AU2000239309A1 publication Critical patent/AU2000239309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2000239309A 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists Abandoned AU2000239309A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008528 WO2001072771A2 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Publications (1)

Publication Number Publication Date
AU2000239309A1 true AU2000239309A1 (en) 2001-10-08

Family

ID=21741219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000239309A Abandoned AU2000239309A1 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Country Status (6)

Country Link
EP (2) EP1383793B1 (enExample)
JP (1) JP2004512010A (enExample)
AT (1) ATE529435T1 (enExample)
AU (1) AU2000239309A1 (enExample)
CA (1) CA2402780A1 (enExample)
WO (1) WO2001072771A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
PL374181A1 (en) 2001-02-09 2005-10-03 Genentech, Inc. Crystallization of igf-1
EP1401476A4 (en) * 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP2272864A3 (en) * 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
EP1812082B1 (en) * 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
ES2558338T3 (es) * 2005-03-25 2016-02-03 National Research Council Of Canada Método para aislamiento de polipéptidos solubles
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
US7659362B2 (en) * 2006-05-30 2010-02-09 Academia Sinica Metal-binding motif compositions and methods
WO2008133961A2 (en) 2007-04-24 2008-11-06 Antyra Inc. Igf-1r binding proteins and antagonists
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
JP2014156401A (ja) * 2011-05-25 2014-08-28 Hoya Corp Ｉｇｆ−１ｒ結合性ペプチド
CN111377773A (zh) * 2020-04-16 2020-07-07 山东省现代中药研究院有限公司 一种含内生菌的花生用海藻复合微生物有机肥

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
DE4432943A1 (de) * 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
EP0832269A1 (en) * 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
RU2078769C1 (ru) * 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
WO1997007827A1 (en) * 1995-08-22 1997-03-06 Thomas Jefferson University Gab1, A Grb2 BINDING PROTEIN, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME
JP2000515726A (ja) * 1996-06-07 2000-11-28 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白をコードする成人ｐｂｍｃ由来のポリヌクレオチド
EP0960335B1 (en) * 1997-01-15 2005-05-25 Telik, Inc. Modulators of insulin receptor activity
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
EP1034188B1 (en) * 1997-11-27 2006-06-07 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor (1-462)
EP1044274A2 (en) * 1998-01-16 2000-10-18 Genzyme Corporation Adenoviral vectors with modified capsid proteins
EP1100890A2 (en) * 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein

Also Published As

Publication number Publication date
WO2001072771A2 (en) 2001-10-04
WO2001072771A3 (en) 2003-12-04
EP2368902A3 (en) 2011-12-21
ATE529435T1 (de) 2011-11-15
EP1383793A2 (en) 2004-01-28
EP2368902A2 (en) 2011-09-28
EP1383793B1 (en) 2011-10-19
CA2402780A1 (en) 2001-10-04
JP2004512010A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2000239309A1 (en) Insulin and igf-1 receptor agonists and antagonists
WO2003070747A3 (en) Insulin and igf-1 receptor agonists and antagonists
Runge et al. Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity
WO2001081408A3 (en) G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
PT2241575E (pt) Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
WO2002072780A3 (en) Igf antagonist peptides
AU2003242352A8 (en) Adiponectin receptor and gene coding for the same
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
WO1998045427A3 (en) Insulin-like growth factor agonist peptides
MX9700822A (es) Composicion cosmetica que contiene un antagonista de los receptores del neuropeptido y.
GB2286398A (en) Human metabotropic glutamate receptors,nucleic acids encoding same and uses thereof
BR9914519A (pt) Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso
IL181311A (en) Variants of neoblastin polypeptide, dimers, conjugates, and fusion proteins that include them, pharmacological compounds based on them, nucleic acids encoding them, and vectors - expression including said nucleic acids, cells containing said vectors, methods for making and using said polypeptides
DK1282437T3 (da) Behandling af brusklidelser
DE69720207D1 (de) Peptide mit spezifischer affinität für pacap typ 1 rezeptoren
WO2001059117A3 (en) Seven-transmembrane proteins/g-protein coupled receptors
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
Abribat et al. Characterization of [125I-Tyr10] human growth hormone-releasing factor (1–44) amide binding to rat pituitary: evidence for high and low affinity classes of sites
GR3030152T3 (en) A human t-cell receptor of the g-protein coupled receptor family
Land et al. Assay for galanin receptor
WO2001049847A3 (en) 26904, 38911, and 39404, seven-transmembrane proteins/g-protein coupled receptors
WO2003012053A3 (en) Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
DE602004027039D1 (de) Cytokinpolypeptidvarianten
WO2005075021A3 (en) Chemically-modified human growth hormone receptor antagonist conjugates
WO2001078796A3 (en) Type ii gonadotropin-releasing hormone receptor and polynucleotides encoding therefor